Table 4 Predicted small molecules and drugs targeting the metastatic uveal melanoma gene signature.
From: Identification of novel chemotherapeutic strategies for metastatic uveal melanoma
Rank | Score | Perturbation | Class* | FDA status* | Indications* |
|---|---|---|---|---|---|
1 | 0.1569 | BRD-K07220430 (Cinnarizine) | Anti-histaminic | Approved | Motion sickness. |
2 | 0.1373 | Digitoxigenin | Unknown | Not approved | None |
3 | 0.1373 | clofazimine | Antimycobacterial | Approved | Leprosy |
4 | 0.1373 | OSSK_645683 | Unknown | Not approved | None |
5 | 0.1373 | MLS-0091942.0001 | Unknown | Not approved | None |
6 | 0.1373 | Mesoridazine besylate | Neuroleptic | Approved | Schizophrenia |
7 | 0.1176 | HDAC6 inhibitor ISOX | Histone deacetylase inhibitor | Not approved | None |
8 | 0.1176 | BRD-K13810148 | Histone deacety-lase inhibitor | Investigational | Â |
9 | 0.1176 | HY-11005 (BX-912) | PDK1 inhibitor | Not approved | None |
10 | 0.1176 | SB 334867 | Orexin antagonist | Not approved | None |
11 | 0.1176 | SC 560 | Cyclooxygenase inhibitors | Not approved | None |
12 | 0.1176 | ERYTHROMYCIN ETHYLSUCCINATE | Macrolide antibiotic | Approved | Bacterial infection |
13 | 0.1176 | Huperzine A [(−)-Huperzine A] | Reversible acetylcholinesterase inhibitor | Investigational | Alzheimer’s disease |
14 | 0.1176 | FLUOCINOLONE ACETONIDE | Glucocorticoid | Approved | Skin disorders |
15 | 0.1176 | PP-110 | Topical anesthetic | Investigational | Hemorrhoids |
16 | 0.1176 | NSC 23766 | RAC1 inhibitor | Â | Â |
17 | 0.1176 | MLS-0390979 | Inhibitor of IAPs | Â | Â |
18 | 0.1176 | NCGC00229596-01 | Unknown | Not approved | None |
19 | 0.1176 | BRD-K73567619 | Unknown | Not approved | None |
20 | 0.1176 | BRD-K24281017 | Unknown | Not approved | None |
21 | 0.1176 | BRD-K06217810 | Unknown | Not approved | None |
22 | 0.1176 | 5922592 | Unknown | Not approved | None |
23 | 0.1176 | BRD-K11778372 | Unknown | Not approved | None |
24 | 0.1176 | 1495 | Unknown | Not approved | None |
25 | 0.1176 | G-220 | Unknown | Not approved | None |
26 | 0.1176 | BRD-K61192129 | Unknown | Not approved | None |
27 | 0.1176 | BRD-K75958195 | Unknown | Not approved | None |
28 | 0.1176 | BRD-K50311478 | Unknown | Not approved | None |
29 | 0.1176 | BRD-K96402602 | Unknown | Not approved | None |
30 | 0.1176 | BRD-K94920105 | Unknown | Not approved | None |
31 | 0.1176 | BRD-K48692744 | Unknown | Not approved | None |
32 | 0.1176 | BRD-K12765235 | Unknown | Not approved | None |
33 | 0.1176 | BRD-K15715913 | Unknown | Not approved | None |
34 | 0.1176 | demeclocycline | Semisynthetic tetracycline antibiotic | Approved | Lyme disease, acne, and bronchitis |
35 | 0.1176 | BRD-K49519144 | Unknown | Not approved | None |
36 | 0.0980 | trichostatin A | Histone deacety-lase inhibitor | Not approved | None |
37 | 0.0980 | Dorsomorphin dihydrochloride | AMPK inhibitor | Not approved | None |
38 | 0.0980 | HDAC6 inhibitor ISOX | Histone deacety-lase inhibitor | Not approved | None |
39 | 0.0980 | 16-HYDROXYTRIPTOLIDE | Unknown | Not approved | None |
40 | 0.0980 | BRD-K92317137 | Unknown | Not approved | None |
41 | 0.0980 | QUINACRINE HYDROCHLORIDE | Anti-helmintic | Approved | Giardiasis, cutaneous leishmaniasis, malignant effusions |
42 | 0.0980 | HDAC6 inhibitor ISOX | Histone deacety-lase inhibitor | Not approved | None |
43 | 0.0980 | BRD-K84203638 | Â | Not approved | None |
44 | 0.0980 | trichostatin A | Histone deacety-lase inhibitor | Not approved | None |
45 | 0.0980 | BRD-K92158425 | Â | Not approved | None |
46 | 0.0980 | topotecan hcl | DNA topoisomerases inhibitor | Approved | Cancer |
47 | 0.0980 | BRD-A60245366 | Unknown | Not approved | None |
48 | 0.0980 | EI-293 | Unknown | Not approved | None |
49 | 0.0980 | S1003 | Unknown | Not approved | None |
50 | 0.0980 | vorinostat | Histone deacetylase inhibitors | Approved | Cutaneous T-cell lymphoma |
